Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nitya Gulati

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Pediatric Hematology and Oncology|January 13, 2021
The global challenge of treating disseminated LCHNitya Gulati
Blood Advances|January 30, 2025
IDCH: is it now determined?Nitya Gulati, Jennifer Picarsic
Blood|October 22, 2020
ALPS or not?Kenneth L McClain, Nitya Gulati
Pediatric Blood & Cancer|June 10, 2023
Do no harm: Distinguishing between rebound thymic hyperplasia and Hodgkin lymphoma relapse in childrenNitya Gulati, Lisa Giulino-Roth
Blood|December 4, 2025
On the CHOPping block? Rethinking initial therapy for PMBCLNitya Gulati, Lisa Giulino-Roth
Transplantation and Cellular Therapy|November 1, 2023
Relapsed/Refractory Primary Mediastinal B-cell Lymphoma: Where do we Stand?Nitya Gulati, Lisa Giulino-Roth
Hematology. American Society of Hematology. Education Program|December 5, 2025
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessmentOlive S Eckstein, Nitya Gulati
Hematological Oncology|June 9, 2021
Langerhans cell histiocytosis: Version 2021Nitya Gulati, Carl E Allen
Blood|March 7, 2024
Old is gold: frontline etoposide for pHLHNitya Gulati, Michelle L Hermiston
Leukemia & Lymphoma|February 24, 2018
Enhancer of zeste homolog 2 (EZH2) inhibitorsNitya Gulati, Wendy Béguelin, Lisa Giulino-Roth
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Pediatric Hematology and Oncology|January 13, 2021
The global challenge of treating disseminated LCHNitya Gulati
Blood Advances|January 30, 2025
IDCH: is it now determined?Nitya Gulati, Jennifer Picarsic
Blood|October 22, 2020
ALPS or not?Kenneth L McClain, Nitya Gulati
Pediatric Blood & Cancer|June 10, 2023
Do no harm: Distinguishing between rebound thymic hyperplasia and Hodgkin lymphoma relapse in childrenNitya Gulati, Lisa Giulino-Roth
Blood|December 4, 2025
On the CHOPping block? Rethinking initial therapy for PMBCLNitya Gulati, Lisa Giulino-Roth
Transplantation and Cellular Therapy|November 1, 2023
Relapsed/Refractory Primary Mediastinal B-cell Lymphoma: Where do we Stand?Nitya Gulati, Lisa Giulino-Roth
Hematology. American Society of Hematology. Education Program|December 5, 2025
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessmentOlive S Eckstein, Nitya Gulati
Hematological Oncology|June 9, 2021
Langerhans cell histiocytosis: Version 2021Nitya Gulati, Carl E Allen
Blood|March 7, 2024
Old is gold: frontline etoposide for pHLHNitya Gulati, Michelle L Hermiston
Leukemia & Lymphoma|February 24, 2018
Enhancer of zeste homolog 2 (EZH2) inhibitorsNitya Gulati, Wendy Béguelin, Lisa Giulino-Roth
Pageof 3